A 48-Week, Double Blind, Randomized, Multinational, Multicentre, "Fixed Combination" Beclomethasone Dipropionate Plus Formoterol Fumarate Versus Formoterol in Patients With Severe Chronic Obstructive Pulmonary Disease.

Trial Profile

A 48-Week, Double Blind, Randomized, Multinational, Multicentre, "Fixed Combination" Beclomethasone Dipropionate Plus Formoterol Fumarate Versus Formoterol in Patients With Severe Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms FORWARD
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 11 Sep 2013 Primary endpoint 'Symptom-exacerbation-rate' has been met according to results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 11 Sep 2013 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met according to results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top